Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (“CKD”) program. The U.S.-based lab was selected for its core competencies in the areas required to support the […]